NASDAQ: MDGL

Madrigal Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for MDGL. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-13.98

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 02:38 UTC.

What Madrigal Pharmaceuticals, Inc. does

The company is a biopharmaceutical business focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. Its lead medication, Rezdiffra, is an oral daily drug that received FDA approval in March 2024 and became the first approved therapy for MASH; it was also approved in Europe and launched in Germany in September 2025.

Summarized from Madrigal Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	8-K 2026-06-17
EPS (TTM)	$-13.98
Debt/equity	0.65

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-11

2026-09-11President and CEOSale-1,539$837.3K
2026-09-11President and CEOSale-215$115.9K
2026-09-11President and CEOSale-131$69.2K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

BAKER BROS. ADVISORS LP2,143,131$1.15B+0.1%
RTW INVESTMENTS, LP1,993,687$1.07B0.0%
Jupiter Topco LLC1,936,099$1.04BNEW

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-12-11Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-04-17Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersRebecca TaubEstimatedSEC 8-K →
2024-02-28Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Questions this page answers

What does Madrigal Pharmaceuticals, Inc. do?

The company is a biopharmaceutical business focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.

When did MDGL last file with the SEC?

Madrigal Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-17. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:38 UTC. This page is also available as JSON at /api/data?ticker=MDGL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MDGL and 5,000+ tickers.

Create a free account — keep MDGL

For your agent

GET /api/data?ticker=MDGL

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt